WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops novel
anticancer therapeutics using its antibody-drug conjugate (ADC)
technology, today announced that the Company will participate in the
Morgan Stanley Global Healthcare Conference. Consistent with the
Conference's format, ImmunoGen President and CEO Daniel Junius will
discuss the Company in a moderated question and answer session that will
be webcast beginning at 9:55am ET on September 8, 2014.
This webcast will be accessible live through the "Investor Information"
section of the Company's website, www.immunogen.com;
a replay will be available at the same location for approximately a week.
The Company also will be participating in one-on-one meetings at the 9th
Annual Citi Biotech ConferenceSeptember 4, 2014 in Boston, MA.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen
cell-killing agent specifically to cancer cells; the Company has also
developed antibodies with anticancer activity of their own. The first
product with ImmunoGen's ADC technology is Roche's Kadcyla®.
ImmunoGen has three wholly owned product candidates in clinical testing
with additional compounds in clinical testing through the Company's
partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More
information about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of
the Roche Group.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com
or
For
Media:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
Source: ImmunoGen, Inc.
News Provided by Acquire Media